DocStoX is a free AI-powered research platform for Indian equity markets, covering 5,700+ NSE & BSE stocks with prices, fundamentals, 326 financial ratios, shareholding, FII/DII flows, F&O, IPOs, a visual screener and AI stock scoring.

Yes. DocStoX has a free tier covering stock research, the screener, FII/DII data and educational guides, plus a free MCP API tier (50 tool calls/day) for AI assistants. A Pro plan adds higher limits and advanced features.

What data does DocStoX cover?

Every NSE & BSE listed stock (5,700+ instruments): EOD and intraday prices, income statement / balance sheet / cash flow, 326 ratios, quarterly shareholding, promoter pledge, mutual-fund holdings, FII/DII flows, F&O and option-chain data, analyst forecasts, IPOs, corporate actions and news.

Can AI assistants like ChatGPT or Claude use DocStoX data?

Yes. DocStoX runs a public Model Context Protocol (MCP) server at https://mcp.docstox.com/mcp with 94 tools, so Claude, ChatGPT, Cursor and other MCP clients can pull Indian market data directly. Setup and a free key are at https://docstox.com/mcp.

Neutral impactCompany

AstraZeneca Pharma India Limited — Product launch

NSE 55 min ago·7 Nov 2026, 6:51 am

AstraZeneca Pharma India

AstraZeneca Pharma India Limited has announced a new product launch, signaling an expansion of its portfolio. This move is likely aimed at strengthening its market presence and capitalizing on growing demand in the healthcare sector.

For investors, this development is a positive indicator of the company's growth strategy. It suggests the firm is actively innovating and seeking to capture new market segments, which could drive future revenue streams.

Investors should monitor the product's market reception and the company's ability to integrate it into its existing operations. Tracking sales performance will be key to understanding the long-term impact of this launch.